NAD+ and Longevity: Reviewing 10 Years of Research

Nicotinamide Adenine Dinucleotide (NAD+) is a coenzyme central to cellular metabolism, found in every living cell. Landmark research by Dr. David Sinclair and others has positioned NAD+ as a key biomarker and potential target in longevity science.

The Decline of NAD+ with Age

Studies consistently show NAD+ levels decline 40–50% between young adulthood and middle age, paralleling the onset of age-related metabolic dysfunction. This decline is attributed to increased consumption by sirtuins, PARPs, and CD38.

Sirtuin Activation

NAD+ is the essential cofactor for sirtuin deacylases (SIRT1–SIRT7). Sirtuins regulate gene expression, DNA repair, and mitochondrial biogenesis — all processes implicated in aging. Research in *Cell* (2013) demonstrated that restoring NAD+ levels in aged mice improved mitochondrial function.

Precursor Research

NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) are NAD+ precursors that have been the subject of multiple human trials. A 2022 study in *Nature Aging* showed NMN supplementation increased blood NAD+ levels and improved muscle insulin sensitivity in older adults.

Conclusion

NAD+ research represents one of the most active areas in longevity science. The mechanistic evidence is compelling, and ongoing human trials are beginning to characterize translational applications.